Open Life Sciences (Jan 2023)

A case of pulmonary embolism with bad warfarin anticoagulant effects caused by E. coli infection

  • Huang Weifeng,
  • Cai Qingqing,
  • Huo Yan,
  • Tang Jin,
  • Chen Yan,
  • Fang Yuan,
  • Lu Yihan

DOI
https://doi.org/10.1515/biol-2022-0539
Journal volume & issue
Vol. 18, no. 1
pp. 29 – 33

Abstract

Read online

Warfarin is an anticoagulant commonly used as an oral drug in preventing and treating thromboembolic diseases. The international normalized ratio (INR) is a clinical monitoring anticoagulation intensity index that adjusts the dose based on important references. In particular, INR value must be strictly monitored when warfarin is used for anticoagulation therapy in infected patients. Herein, we report a 54-year-old female patient diagnosed with pulmonary embolism and venous thrombosis of the lower limbs. After the warfarin administration, the INR was always substandard. The patient did not take other warfarin-interacting drugs or foods during the hospital stay. Metagenome next-generation sequencing suggested a bloodstream infection caused by Escherichia coli, which was further confirmed by blood culture. After meropenem administration for anti-infective treatment, the INR value rose rapidly to a standard level. Considering the lack of relevant reports, this case is the first report of potential interaction between E. coli and warfarin. Further, in patients with thromboembolic diseases complicated by infection, antibiotics should be chosen reasonably with close monitoring of the INR to avoid the interaction of warfarin and antibiotics and to ensure the effectiveness and safety of warfarin treatment.

Keywords